What is CRITERIUM?
Criterium operates as a full-service Clinical Research Organization (CRO) with a legacy spanning over three decades. The company distinguishes itself through a comprehensive suite of clinical trial solutions designed to optimize cost-efficiency and accelerate the path to regulatory market approval. Their service portfolio encompasses end-to-end clinical trial management, retrospective studies, and proprietary technology platforms. With deep-seated expertise in therapeutic areas such as oncology, dermatology, and orthopedics, Criterium maintains a specialized focus on complex cancer research. Their strategic advantage is further bolstered by robust collaborative networks with premier academic institutions across the United States and Canada, facilitating high-impact translational research that bridges the gap between laboratory discovery and clinical application.
How much funding has CRITERIUM raised?
CRITERIUM has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in CRITERIUM
PPP
Public-Private Partnership
What's next for CRITERIUM?
With the successful closure of this late-stage financing, Criterium is poised to enter a new phase of growth characterized by technological integration and expanded research capacity. The capital will likely be deployed to enhance their digital trial management capabilities, allowing for more agile data collection and analysis in increasingly complex therapeutic environments. As the pharmaceutical industry continues to prioritize faster time-to-market metrics, Criterium's focus on streamlining the clinical development lifecycle positions them as a critical partner for research institutions and drug developers alike. Future strategic initiatives will likely involve scaling their oncology research division and deepening their academic partnerships to maintain their competitive edge in translational medicine.
See full CRITERIUM company page
